Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness

Marquina, Clara, Zomer, Ella, Vargas-Torres, Sandra, Zoungas, Sophia, Ofori-Asenso, Richard, Liew, Danny, Ademi, Zanfina · 2020 · PharmacoEconomics

Abstract

Background New pharmacological therapies for the treatment of cardiovascular disease (CVD) have emerged in recent years. The high rates of CVD and the need for long-term treatment to decrease risk factors makes cost-effectiveness crucial for their successful long-term implementation. Objective This study assessed cost-effectiveness studies of novel pharmacological treatments (ezetimibe, proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors, omega-3 polyunsaturated fatty acids [n-3 PUFAs], and the cardiovascular polypill) compared with standard care for the secondary prevention of CVD. Methods We searched seven databases and the reference list of selected literature reviews for eligible cost-effective analyses (CEA) published between January 2009 and January 2020 that evaluated the above novel treatments versus standard care. Two independent reviewers performed the screening and evaluation in accordance with the Consolidated Health Economic Evaluation Reporting Standards statement. Cost results were adapted to 2018 US dollars (US$) to facilitate comparisons between studies. Consideration of cost-effectiveness was based on the original study criteria. Results Thirty-two studies were included in this review, most of them adopting a healthcare perspective. Studies evaluating ezetimibe, PCSK9 inhibitors and n-3 PUFAs assessed their addition to standard care compared with standard care alone, while studies analysing the polypill evaluated the replacement of multiple mono…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40273-020-00936-0

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 76 · Cited by 34

Research works printed but not linked: 1

  1. Excellence NIfHaC. Guide to the methods of technology appraisal 2013. London: NICE; 2013 (Accessed 15 April 2020).

Metadata

Authors
Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z.
Affiliations
Monash University (AU)
Corresponding author
Ademi, Zanfina
Venue
PharmacoEconomics
Published
2020-06-25
Volume
38
Issue
10
Pages
1095-1113
ISSN
  • 1170-7690 (ISSN-L)
  • 1179-2027
OpenAlex
W3037786329
Cited by
34
References
76
Citations by year
2026: 1 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 11 · 2021: 5 · 2020: 2
FWCI
1.30
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
secondary prevention, cardiovascular disease, cost-effectiveness, ezetimibe, PCSK9 inhibitors, omega-3 polyunsaturated fatty acids, fixed-dose combination, lipid-lowering therapy, incremental cost-effectiveness ratio, healthcare perspective, cardiovascular risk reduction, statins, ezetimibe-simvastatin combination, LDL cholesterol lowering
MeSH terms
Proprotein Convertase 9, Anticholesteremic Agents, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. https://app.cochat.ai/papers/10.1007/s40273-020-00936-0
The paper
Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020). Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. PharmacoEconomics. https://doi.org/10.1007/s40273-020-00936-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.